An FDA-approved universal cure for all major forms of cancer is available before 2035.

Question

Six frontier AI models put this at 1% by 1 Oct 2036. Full reasoning from every model.

WillHappen.ai · Accepted Answer

1% — the median of 6 frontier models, resolving by 2036-10-01.

Answer

Gemini (Google): 1% — Cancer's extreme genetic heterogeneity makes a single therapeutic mechanism clearing all major solid tumors biologically near-impossible. No pan-cancer universal target exists across lung, breast, colorectal, and prostate malignancies despite decades of research. FDA drug development takes 10 to 15 years, meaning any 2035 cure would already need to be in Phase II trials today. Broad-spectrum approaches like universal CAR-T or mRNA vaccines remain tailored to subsets and lack pan-histology curative efficacy.

Answer

Claude (Anthropic): 1% — No single therapy can plausibly cure all major solid tumor types given cancer's biological heterogeneity. Cancer comprises genetically distinct diseases with different drivers, so a 'universal cure' contradicts current oncology science. Even best immunotherapies (CAR-T, checkpoint inhibitors) only work on subsets of cancers, with no sign of a unifying mechanism emerging. FDA approval requires clinical trials across tumor types, a regulatory and scientific bar far beyond any plausible breakthrough by 2036.

Answer

GPT (OpenAI): 1% — A single therapy must show durable cures across biologically disparate solid tumors in FDA-grade trials by 2035. FDA approvals are indication-specific; no prior drug has cured even most major solid-tumor classes, much less all of them. Universal tumor targeting must clear resistance, microenvironment, toxicity, and durable-survival evidence across many pivotal programs. I would raise this sharply only if one platform produced replicated, long-term complete responses across tumor types in trials by 2030.

Answer

Grok (xAI): 1% — No pan-cancer single agent exists or is in late trials; 9 years cannot produce one. FDA approval requires a completed Phase 3 program showing durable complete responses across lung, breast, colorectal, prostate and other major solid tumors. Historic base rate of any pan-indication oncology approval is zero; even CAR-T and checkpoint inhibitors remain lineage- or mutation-restricted. A shared, targetable pan-solid-tumor vulnerability would have to be discovered, de-risked and trialed starting from scratch after 2026, which no current pipeline or…

Answer

DeepSeek (DeepSeek): 1% — A single therapy curing every major cancer type is biologically implausible; even pan-tumor drugs like pembrolizumab only work in subsets. FDA has approved ~1000 cancer drugs since 1971, none pan-tumor curative; even tissue-agnostic approvals (pembrolizumab 2017, larotrectinib 2018) cover <1% of patients. Cancer's 100+ types have distinct driver mutations, microenvironments, and immune evasion tactics; a universal cure would require solving all simultaneously, which no… The only development that would change my mind is a single agent showing durable complete responses across multiple phase 3 trials in unrelated solid tumors by 2033…

Answer

Qwen (Alibaba): 2% — Cancer is >100 genetically distinct diseases; no single mechanism could plausibly cure all major solid tumors within 9 years. No therapy in history has cured even one solid tumor type across all subtypes; the biological heterogeneity makes a universal mechanism implausible. Even the most promising platform approaches (CAR-T, bispecifics, mRNA vaccines) target specific antigens and face tumor-specific resistance. Would need to see a Phase III trial showing durable complete response across pancreatic, glioblastoma, and other hard-to-treat cancers simultaneously—no such trial…

An FDA-approved universal cure for all major forms of cancer is available before 2035.

The FDA issues a decision on the drug candidate with a target date of October 9, 2026.

An FDA-approved treatment that reverses or fully halts cognitive decline in Alzheimer's disease becomes available before 2035.

A curative treatment for at least three of the top five deadliest cancers is approved by the FDA before October 2036.

A universal cure or vaccine effectively eliminating cancer mortality across most major types is approved by regulatory agencies before 2040.